Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
Follow WINT
Windtree Therapeutics, Inc. (WINT) EV/Sales
As of 16 October 2026, Windtree Therapeutics, Inc. (WINT) trades at a EV/Sales of 63.8×. Over the past ten years it has ranged from 15.5× (September 2023) to 145,624,429× (March 2015); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 223× | (99.99%) |
| FY2018 | 1,696,183× | 256.56% |
| FY2017 | 475,703× | (31.90%) |
| FY2016 | 698,516× | (98.77%) |
| FY2015 | 56,976,197× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2019 | 223× | 17.62% |
| Jun 2019 | 190× | 149.75% |
| Mar 2019 | 75.9× | (100.00%) |
| Dec 2018 | 1,696,183× | 76.23% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.7× |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. compare | 23.3× |
| WINT Windtree Therapeutics, Inc. | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)